Research programme: peginterferon lambda - AmbrxAlternative Names: PEG-INF lambda - Ambrx; Pegylated interferon lambda - Ambrx
Latest Information Update: 16 Jul 2016
At a glance
- Originator Ambrx
- Class Interferons
- Mechanism of Action Interleukin 29 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (Parenteral)
- 21 May 2013 Preclinical trials in Hepatitis C in USA (Parenteral)